EGFR and non-small cell lung carcinoma: Another phase II clinical study of ILLUMINATE explored the efficacy and safety of dual immunotherapy (anti‐PD‐L1 durvalumab and anti‐CTLA4 tremelimumab) combined with chemotherapy in metastatic EGFR‐mutation‐positive NSCLC that has progressed after EGFR‐TKI resistance (NCT03994393).